~ Pfizer commits an additional $1.5 million in support to Canadian
researchers and launches two new awards ~
TORONTO, Oct. 27 /CNW/ - Pfizer Canada is pleased to announce the fifth
round of recipients of the Pfizer Cardiovascular Research Awards Program. The
program, first launched in October 2005, was developed to fund and support
cardiovascular research in Canada.
This year, Pfizer Canada is pleased to introduce two new distinguished
awards: The Kidney Foundation of Canada/Pfizer Canada - Cardio-Renal Research
Award and The Canadian Hypertension Society - Pfizer Award.
A unique and innovative alliance between The Kidney Foundation of Canada,
a national health charity and Pfizer Canada, The Kidney Foundation of
Canada/Pfizer Canada - Cardio-Renal Research Award will fund research projects
to address the cardiovascular complications of kidney disease. This year's
recipient is Dr. Rhian M. Touyz, Professor of Medicine and Senior Scientist at
the University of Ottawa.
"Existing research shows there may be a direct correlation between kidney
disease and the progression of cardiovascular disease. Further research in
this area is vital to understand the complexity of cardiovascular disease in
Canada," says Dr. Touyz.
The Canadian Hypertension Society - Pfizer Award, a collaboration with
the Canadian Hypertension Society (CHS) and Pfizer Canada supports the best
independent research on hypertension in Canada. Dr. Anne Monique Nuyt,
Associate Professor at the Université de Montréal is this year's winner.
"Affecting more than five million Canadians, hypertension is a leading
risk factor for death in North America, which now affects younger and younger
individuals and even a rising number of children" says Dr. Nuyt. "I am pleased
to receive this honour to help further our understanding and treatment of
hypertension in Canada."
The Pfizer Cardiovascular Research Awards Program aims to fund and
support independent cardiovascular research in the areas of basic, biomedical
and clinical sciences, patient care enhancement, epidemiology and outcome
research. All proposals are reviewed and selected by an independent committee
of 17 Canadian cardiovascular experts, chaired by Dr. Jean-Claude Tardif,
Director of Research, Montreal Heart Institute, Professor of Medicine,
Université de Montréal.
"We are very pleased with the overwhelming response from medical
professionals interested in cardiovascular research," says Dr. Tardif.
"Medical research and development is vital to our understanding and treatment
of cardiovascular disease. Through this contribution, Pfizer is demonstrating
its commitment to supporting independent cardiovascular research in Canada."
Award recipients are announced at the Canadian Cardiovascular Congress in
- Dr. Richard Lehner, Associate Professor, University of Alberta
- Dr. Shelagh B. Coutts, Assistant Professor, University of Calgary
- Dr. John S. Hill, Associate Professor, University of British Columbia
- Dr. Martin James O'Donnell, Assistant Professor, McMaster University
- Dr. Minna Woo, Assistant Professor, University of Toronto
- Dr. Peter P. Liu, Professor, University of Toronto (Toronto, ON),
winner of The Jean Davignon Distinguished Cardiovascular-Metabolic
- Dr. Anne Monique Nuyt, Associate Professor, Université de Montréal
(Montreal, QC), winner of The Canadian Hypertension Society - Pfizer
- Dr. Rhian M. Touyz, Professor, University of Ottawa (Ottawa, ON),
winner of The Kidney Foundation of Canada/Pfizer Canada - Cardio-Renal
Pfizer Canada is proud to support the innovators and ideas that make
better health possible. "Pfizer's mission is to support outstanding research
with the potential to improve the cardiovascular health and quality of life of
Canadians," says Dr. Bernard Prigent, Vice President and Medical Director,
Pfizer Canada. "We will continue to invest in Canadian research to generate
scientific knowledge that may ultimately lead to an improvement of the
understanding and treatment of cardiovascular disease in Canada."
CARDIOVASCULAR DISEASE IN CANADA
Cardiovascular disease, including heart disease and stroke, is the
leading cause of death in Canada.(1) Unfortunately, Canadians run a high risk
of developing cardiovascular disease as 80 per cent of Canadians have at least
one modifiable risk factor for cardiovascular disease, such as high
cholesterol, hypertension, smoking, obesity and a sedentary lifestyle.(2)
ABOUT PFIZER CANADA INC.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world's
leading pharmaceutical company. Pfizer discovers, develops, manufactures and
markets prescription medicines for humans and animals. Pfizer's ongoing
research and development activities focus on a wide range of therapeutic areas
following our guiding aspiration: working together for a healthier world. For
more information, visit www.pfizer.ca.
(2) Tipping the Scales of Progress. Heart Disease and Stroke in Canada,
2006. Heart and Stroke Foundation of Canada.
accessed July 16, 2008.
For further information:
For further information: or to arrange an interview with an award
recipient, please contact Carolyn Santillan/Laura Espinoza, Edelman,
firstname.lastname@example.orgemail@example.com, (416) 979-1120 ext.
351/245; Christian Marcoux, Pfizer Canada Inc., firstname.lastname@example.org,